Recurrent <i>ETV3</i>::<i>NCOA2</i> fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis
sponsorship: The authors thank the immunohistochemical laboratory of Leiden University Medical Center for performing additional immunohistochemical stains. The authors also thank A. Beishuizen (Princess Maxima Center for Pediatric Oncology) , D.J.P. Willemsen (Anna Hospital) , A.M. van Tuyll van Serooskerken (Haga Hospital) , and D. Dittmar (University Medical Center Gro-ningen) for providing clinical data and/or images of individual patients.This study was funded by a grant from Stichting de Merel (P.G.K., T.v.W., A.G.S.v.H., and P.C.W.H.) . F.J.S.H.W.-A.-J. personally financed routine molecular diagnostic tests for her patients when these were not reimbursed. P.G.K. received an MD/PhD grant from Leiden University Medical Center. T.T. holds a Mandate for Fundamental and Translational Research from the "Stichting tegen Kanker" (2014-083 and 2019-091) and is supported by the ME TO YOU Foundation. I.V.B. is a recipient of a postdoctoral fellowship sponsored by the Clinical Council for Research and Education from University Hospitals Leuven. (Stichting de Merel, Leiden University Medical Center, ME TO YOU Foundation, Mandate for Fundamental and Translational Research from the "Stichting tegen Kanker"|2014-083, Mandate for Fundamental and Translational Research from the "Stichting tegen Kanker"|2019-091, Clinical Council for Research and Education from University Hospitals Leuven)
Authors
- Pancras C.W. Hogendoorn (ORCID: https://orcid.org/0000-0002-1513-8104)
- Astrid G. S. van Halteren (ORCID: https://orcid.org/0000-0002-0563-4155)
- Marijn Scheijde-Vermeulen
- Koen D. Quint (ORCID: https://orcid.org/0000-0002-3267-5630)
- Jan van Laar (ORCID: https://orcid.org/0000-0002-8885-4929)
- Marco J. Koudijs
- Konnie M. Hebeda (ORCID: https://orcid.org/0000-0002-4181-3302)
- Joost F. Swennenhuis (ORCID: https://orcid.org/0000-0001-7030-6804)
- Tom van Wezel (ORCID: https://orcid.org/0000-0001-5773-7730)
- Robert M. Verdijk (ORCID: https://orcid.org/0000-0003-1437-214X)
- Esther Hauben (ORCID: https://orcid.org/0000-0001-8688-9231)
- Patty M. Jansen (ORCID: https://orcid.org/0000-0002-2361-9303)
- Gilles F.H. Diercks (ORCID: https://orcid.org/0000-0001-8053-216X)
- Ellen Stelloo (ORCID: https://orcid.org/0000-0002-1264-3594)
- Feng Jung Sherida H. Woei-A-Jin (ORCID: https://orcid.org/0000-0001-7840-6156)
- Ruben H.P. Vorderman (ORCID: https://orcid.org/0000-0002-8813-1528)
- Paul G. Kemps (ORCID: https://orcid.org/0000-0001-9793-7032)
- Isabelle Vanden Bempt (ORCID: https://orcid.org/0000-0002-3433-555X)
- Annette H. Bruggink (ORCID: https://orcid.org/0000-0003-1354-6988)
- Cor van den Bos (ORCID: https://orcid.org/0000-0002-6175-6077)
- Arjen H.G. Cleven (ORCID: https://orcid.org/0000-0002-3672-4348)
- Thomas Tousseyn (ORCID: https://orcid.org/0000-0002-0397-1086)
- Leonie Naeije
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Universitair Ziekenhuis Leuven (BE)
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- Emma Kinderziekenhuis (NL)
- Center for Human Genetics (US)
- Polpharma Biologics (Netherlands) (NL)
- Cergentis (Netherlands) (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Princess Máxima Center (NL)
- Amsterdam University Medical Centers (NL)
- Catholic University of America (US)
- Nationwide Mutual Insurance Company (United States) (US)
- Erasmus University Rotterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Blood Advances
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1182/bloodadvances.2024013696
- Citations
- 8
- Primary Topic
- Histiocytic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.61
Funders
- Universiteit Leiden
- Leids Universitair Medisch Centrum
- Universitair Medisch Centrum Groningen